药物基因组学和药物蛋白质组学杂志

抽象的

Human Immunodefieciency Virus: Pharmacogenetics of Antiretroviral Treatment

Susana A Pesoa, Cristian A Galván Bioch, Dante M Beltramo, Néstor W Soria

The introduction of highly active antiretroviral therapy as standard of care has considerably enhanced the life expectancy among HIV-infected individuals. Although this combination of drugs virtually suppresses viral replication, the therapeutic effect may be limited by differing rates of adverse events and responses in terms of efficacy and toxicity. These differences arise from complex interactions between biological and environmental factors. Pharmacogenetic studies are contributing to our understanding of the inter-individual differences in the response to antiretroviral drugs. Several studies have provided a relevant number of associations between human genetic variants and predisposition to adverse events and for some antiretroviral drugs clear and causal genotype–phenotype correlation has been established. These findings make the idea of personalized medicine in this field increasingly attractive. We will discuss here current achievements on pharmacogenetics of HIV treatment with special emphasis on the genetic polymorphisms underlying toxic effects and/or those already implemented in the clinical setting.